Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Protalix BioTherapeutics, Inc.AMEX: PLX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $5.43M rose 56.1% year over year, behind the +58.7% change in trailing-twelve-month research & development. Sequentially, it fell 3.7% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.

Context

  • Research & development amounted to 36.1% of revenue in FY2025, up 11.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +56.1% toward the trailing-twelve-month pace of +58.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.43M-3.7% QoQ
Last fiscal yearDec 2025
$19.05M+46.9% YoY
LTMMar 2026
$21.52M+58.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.1%——
1 year+46.9%——
3-year CAGR-13.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
19.05M USD
Year-over-year change
+46.9%
4-year CAGR
-10.5%

Research & Development vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's LTM Mar 2026 research & development of $21.52M is the 3rd highest of the 4 companies compared; the peer median is $104.71M.
  • Its year-over-year change of +58.7% is the highest of 3, against a peer median of +17.3%.
  • Research & development amounts to 28.2% of revenue for PLX, versus a peer median of 71.8%.
PLX Competitors Peer median
Research & Development for PLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$770.95M +12.5%+2.0%115.2%
PHARPharming Group N.V.LTM Mar 2026$104.71M +22.1%+23.1%28.3%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$21.52M +58.7%-13.4%28.2%
PLYXPolaryx Therapeutics, Inc. Common StockLTM Mar 2026$2.23M ———
Peer median (excluding PLX) $104.71M+17.3%+12.6%71.8%

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.35M47.64M65.49M53.4M52.74M
Cost of Revenue16.35M19.59M22.98M24.32M27.51M
Gross Profit22M28.05M42.51M29.08M25.24M
Gross Margin57.4%58.9%64.9%54.5%47.8%
Research & Development29.73M29.35M17.09M12.97M19.05M
Selling, General & Admin12.73M11.71M14.96M12.19M11.68M
Operating Expenses42.46M41.06M32.05M25.16M30.74M
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
EBITDA(18.94M)(10.78M)12.94M6.52M(2.95M)
EBITDA Margin-49.4%-22.6%19.8%12.2%-5.6%
Operating Income(20.46M)(13.01M)10.46M3.92M(5.5M)
Operating Margin-53.4%-27.3%16.0%7.3%-10.4%
Interest Income401K1.15M1.29M1.3M1.08M
Interest Expense7.52M2.53M3.18M1.06M1.19M
Other Income / Expenses(7.12M)(1.38M)(1.89M)237K(108K)
Income Before Tax(27.58M)(14.4M)8.57M4.15M(5.61M)
Pre-Tax Margin-71.9%-30.2%13.1%7.8%-10.6%
Income Tax Expense0530K254K1.22M996K
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Net Margin-71.9%-31.3%12.7%5.5%-12.5%
EPS (Basic)(0.62)(0.31)0.120.04(0.08)
EPS (Diluted)(0.62)(0.31)0.100.04(0.08)
Weighted Avg Shares44.14M48.47M67.51M72.53M78.55M
Weighted Avg Shares (Diluted)44.14M48.47M82.42M81.06M78.55M

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.